Agarwal Discusses the Updated Results of the TITAN Trial of Apalutamide in mHSPC
Neeraj Agarwal, MD, discusses the updated results of the phase 3 TITAN study, which analyzed the efficacy of apalutamide plus androgen deprivation therapy versus ADT plus placebo in patients with metastatic hormone-sensitive prostate cancer.
EP: 1.Case 1: 64-Year-Old African American Man With nmCRPC
EP: 2.Case 1: The Importance of PSA Doubling Time in Prostate Cancer
EP: 3.Case 1: Initiating Patients on AR-Targeted Therapy in nmCRPC
EP: 4.Case 1: Differences in AR-Targeted Therapy Adverse Events in nmCRPC
EP: 5.Case 1: Patient Choice in Initiating AR-Targeted Therapy in nmCRPC
EP: 6.Case 2: 64-Year-Old White Male With mCSPC
EP: 7.Case 2: High-Volume Versus Low-Volume Metastatic CSPC
EP: 8.Case 2: Combination Therapy Options in Metastatic CSPC
EP: 9.Case 2: Challenges Treating CSPC With Visceral Metastases
EP: 10.Case 2: Sequencing Therapy in mCSPC
EP: 11.Case 2: Local Control in Metastatic CSPC
EP: 12.Case 3: 72-Year-Old Man With mCRPC
EP: 13.Case 3: Factors to Consider in mCRPC Treatment
EP: 14.Case 3: Treatment After Progression to mCRPC
EP: 15.Case 3: Personalizing Treatment for mCRPC
EP: 16.Case 3: Clinical Relevance of the AR-V7 Biomarker in mCRPC
EP: 17.Case 3: Use of Radium-223 in mCRPC
EP: 18.Additional Insights: The Presentation of Prostate Cancer
EP: 19.Additional Insights: Novel Agents in Prostate Cancer
EP: 20.Additional Insights: Androgen Receptor Inhibitor Adverse Events
EP: 21.Additional Insights: Management of Toxicities in AR Therapy
EP: 22.Additional Insights: Keeping Up With Advances in Prostate Cancer
EP: 23. Agarwal Discusses the Updated Results of the TITAN Trial of Apalutamide in mHSPC
Neeraj Agarwal, MD, the senior director of clinical research innovation at the Huntsman Cancer Institute, discusses the updated results of the phase 3 TITAN study (NCT02489318), which analyzed the efficacy of apalutamide (Erleada) plus androgen deprivation therapy (ADT) versus ADT plus placebo in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
According to Agarwal, the study led to the approval of apalutamide in this patient population. In total, 1052 patients were enrolled and were randomized 1:1 to each treatment arm. At a median follow-up of 22.7 months, the combination was associated with significant overall survival and progression-free survival (PFS) benefit over the placebo.
Eventually, the study was unblinded, according to Agarwal. This led to a 40% crossover from the placebo arm to the combination arm. Even with this crossover, at 44 months, the combination was associated with a 35% reduction in the risk of death compared to the placebo.
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
September 18th 2023A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Listen
BXCL701 Gains Fast Track Designation for mCRPC Treatment
February 13th 2024The FDA has granted fast track designation to BXCL701 with an immune checkpoint inhibitor for metastatic small cell neuroendocrine prostate cancer resistant to chemotherapy and showing no evidence of microsatellite instability.
Read More
